Ornim Medical is an Israeli bio-medical high-technology company specializing in clinical research, development, and distribution of the highest quality medical devices for non-invasive patient monitoring specializing in the field of tissue and cerebral blood flow. Its two products, the CerOx™ and the c-FLOW™, are bedside patient monitors based on the patented UTLight™ technology designed to provide physicians with unique monitoring solutions that are imperative to individualized and personalized patient care. Both products enable precise, real time, continuous and non-invasive measurements of cerebral blood flow alerting physicians to variations in blood flow to the brain, thus enabling informed intervention for better clinical results and patient care. Ornim’s CerOx™ monitor is the only device in the market today enabling simultaneous, non-invasive measurement of both blood flow and oxygen saturation; while the c-FLOW™ is a pared down version used to measure the CBF only. The use of either of these products (depending on the clinical setting) is key to understand perfusion while helping to direct treatment and lower the cost of patient care. Ornim’s unique technology, protected by 13 worldwide granted and 15 worldwide pending patents, overcome limitations of Near Infrared Spectroscopy (NIRS) and ultrasound Doppler. The patented UTLight™ technology employs the combination of light and ultrasound to provide a non-invasive measure of regional blood oxygen saturation and blood flow. UTLight™ technology is unique among all other commercially available NIRS technologies, since it also analyzes the light speckle signal and does not rely solely on the intensity of light reaching the detector. Ornim Medical has developed a product range that was born out of a need – a need to measure blood flow directly. In other words, the products have the capabilities of direct measurement of flow (not surrogate like tissue oximetry); they are intuitive and comprehensive; actionable; the management of blood pressure (BP) according to CBF is intuitive; the measurement is robust and finally they are when adding the BP signal, the Autoregulation function of the organ can be assessed directly.

Ornim Medical is an Israeli bio-medical high-technology company specializing in clinical research, development, and distribution of the highest quality medical devices for non-invasive patient monitoring specializing in the field of tissue and cerebral blood flow. Its two products, the CerOx™ and the c-FLOW™, are bedside patient monitors based on the patented UTLight™ technology designed to provide physicians with unique monitoring solutions that are imperative to individualized and personalized patient care. Both products enable precise, real time, continuous and non-invasive measurements of cerebral blood flow alerting physicians to variations in blood flow to the brain, thus enabling informed intervention for better clinical results and patient care. Ornim’s CerOx™ monitor is the only device in the market today enabling simultaneous, non-invasive measurement of both blood flow and oxygen saturation; while the c-FLOW™ is a pared down version used to measure the CBF only. The use of either of these products (depending on the clinical setting) is key to understand perfusion while helping to direct treatment and lower the cost of patient care. Ornim’s unique technology, protected by 13 worldwide granted and 15 worldwide pending patents, overcome limitations of Near Infrared Spectroscopy (NIRS) and ultrasound Doppler. The patented UTLight™ technology employs the combination of light and ultrasound to provide a non-invasive measure of regional blood oxygen saturation and blood flow. UTLight™ technology is unique among all other commercially available NIRS technologies, since it also analyzes the light speckle signal and does not rely solely on the intensity of light reaching the detector. Ornim Medical has developed a product range that was born out of a need – a need to measure blood flow directly. In other words, the products have the capabilities of direct measurement of flow (not surrogate like tissue oximetry); they are intuitive and comprehensive; actionable; the management of blood pressure (BP) according to CBF is intuitive; the measurement is robust and finally they are when adding the BP signal, the Autoregulation function of the organ can be assessed directly.

The TRIMEDX CYBER Advanced offering, in partnership with Medigate, an industry leading IoMT provider, delivers deep integration and live, dynamic collection of data on each of your connected medical devices. This data collection includes: • Known clinical assets connected to the network • Additional connected clinical assets identified through MDSP technology • Connected clinical assets added to network on an ongoing basis • Percentage completeness of the collection of critical data points for clinical assets Our dedicated CYBER Specialists monitor 40+ intelligence sources to identify vulnerabilities, advocate with OEMs to acquire OEM-validated patches, apply appropriate patches or compensating controls if no patch is available and fully track all remediation efforts. Through the ongoing visibility provided by this process, clients have access to the comprehensive TRIMEDX CYBER Risk Score, real-time cyber alerting capabilities and greater inventory accuracy, allowing for a more accurate understanding of your cybersecurity risk, while enabling faster identification/location of equipment in the event of a cybersecurity threat.

As the largest independent, technology-enabled clinical asset management company in the United States, TRIMEDX provides strategic planning and management of clinical assets to drive operational cost savings, free up capital for new strategic initiatives and deliver improved risk management and cyber protection.